Full Press Release Details
SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that members of its senior management team will participate in the following investor conferences:
| TD Cowen 44 th Annual Global Health Care Conference | ||
| Type: | Presentation and one-on-one investor meetings | |
| Speaker: | Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer | |
| Date: | Wednesday, March 6, 2024 | |
| Presentation Time: | 2:10pm ET / 11:10am PT | |
| Location: | Boston, MA | |
| Leerink Partners Global Biopharma Conference 2024 | ||
| Type: Date: Location: | One-on-one investor meetings Wednesday, March 13, 2024 Miami, FL |
A live webcast of the presentation may be accessed on the Events page of Turnstone’s Investor Relations website at https://ir.turnstonebio.com, where a replay will also be available for a limited period.
Institutional investors interested in meeting with members of Turnstone’s senior management team during the conferences may contact their respective representatives at TD Cowen and Leerink Partners for further information.
Tags
Selected TIL Therapy